|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Management Strategies for Low-Grade Intermediate-Risk Bladder Cancer
|
Sarah Psutka, MD, MS
Zachary Klaassen hosts Sarah Psutka to discuss low-grade, intermediate-risk NMIBC. She emphasizes the importance of shared decision-making to balance escalation versus de-escalation, focusing on reducing recurrence burden while acknowledging the non-lethal nature of the disease.
|
|
|
|
|
|
|
|
|
|
|
| Risk Stratification for Active Surveillance in Low and Intermediate-Risk Bladder Cancer |
|
Marco Moschini, MD, PhD
|
| Ashish Kamat speaks with Marco Moschini about expanding active surveillance criteria for recurrent low-grade bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
Active Surveillance vs TURBT for Low-Grade Ta Bladder Cancer
|
Morgan Rouprêt, MD, PhD, Laura Bukavina, MD, MPH, MSc
Ashish Kamat discusses active surveillance for low-grade Ta bladder cancer with Morgan Rouprêt and Laura Bukavina.
|
|
|
|
|
|
|
|
|
|
|
| Treatment of High-grade NMIBC: Results from the VERSUS Study |
| Christian Doehn, MD, PhD |
| In the German VERSUS registry, only about 70% of patients with high‑grade NMIBC received intravesical BCG, despite guideline support, with BCG use increasing by risk stage. Mitomycin C—most often at a reduced 20 mg dose—was used in 30% of cases without clear tailoring to tumor features, and substantial missing grading data highlight both underuse of BCG and heterogeneous real-world practice patterns across NMIBC, reinforcing the need for more consistent, risk-adapted treatment strategies.. |
|
|
|
|
|
| Clinical Validation of the International Bladder Cancer Group's Intermediate-risk Non-muscle-invasive Bladder Cancer Stratification Model
|
| Jayant Siva, MD
|
| At the EAU 2026 Annual Meeting, Dr. Jayant Siva presented findings from a large validation study assessing the performance of the International Bladder Cancer Group (IBCG) clinical risk model in intermediate-risk NMIBC.
|
|
|
|
|
|
|
|
|
|
|
| Reduced Versus Full Dose BCG Maintenance in NMIBC Patients Treated with Full Dose Induction: A Matched Analysis
|
| Alexandre Zlotta, MD, PhD, FRCSC
|
| This multicenter matched cohort found that, in intermediate/high‑risk NMIBC patients who all received full‑dose BCG induction, using a reduced‑dose BCG for maintenance did not worsen progression, cancer‑specific survival, or overall survival compared with full‑dose maintenance. Interestingly, reduced‑dose maintenance was associated with better recurrence‑free survival, supporting the rationale for a randomized trial of full versus reduced maintenance dosing in the context of ongoing BCG shortages.
|
|
|
|
|
|
| Impact of BCG Failure Pattern on Oncologic Outcomes of Intravesical Gemcitabine and Docetaxel in High-Risk NMIBC: A Multicenter European Study |
| Pietro Scilipoti, MD |
| This multicenter European series found that intravesical therapies can be effective and well tolerated across different NMIBC recurrence patterns, with outcomes varying by prior treatment exposure and disease characteristics. |
|
|
|
|
|
| Blue-light Guided Transurethral Laser Ablation for NMIBC: First UK Single-Center Experience on RFS
|
| Aaryan Sandhu
|
| At the EAU 2026 Annual Meeting, Aaryan Sandhu presented early data on blue-light–guided transurethral laser ablation as a minimally invasive approach in NMIBC.
|
|
|
|
|
|
|
|
|
|
|
